Safety of the 15-valent pneumococcal conjugate vaccine: A phase I clinical trial

Area of Science:

• Immunology
• Vaccinology
• Pediatrics

Background:

• Pneumococcal conjugate vaccines are crucial for preventing invasive pneumococcal disease.
• PCV15 is a novel vaccine developed to broaden protection against pneumococcal serotypes.
• Evaluating vaccine safety in diverse age groups, including infants, is essential.

Purpose of the Study:

• To assess the safety and tolerability of the 15-valent pneumococcal conjugate vaccine (PCV15) in healthy infants.
• To identify and characterize adverse events (AEs) and serious adverse events (SAEs) following PCV15 vaccination.
• To compare safety profiles across different age cohorts, including infants, children, and adults.

Main Methods:

• A Phase I clinical trial involving 80 subjects across four age groups: adults (≥18 years), children (1-5 years), infants (3 months), and younger infants (≥6 weeks).
• Vaccination schedules included single doses for adults and children, and three-dose schedules for infants (0, 1, 2 months or 0, 2, 4 months).
• Adverse events were monitored for 30 days post-dose, and serious adverse events for 6 months post-vaccination.

Main Results:

• Solicited and unsolicited AE frequencies and laboratory indices were similar across all treatment groups.
• No vaccine-related serious adverse events (SAEs) were reported during the study period.
• The most common vaccine-related AEs were mild systemic and local reactions, primarily fever and pain. One case of hypersensitivity (urticaria) was noted in the younger infant group.

Conclusions:

• The 15-valent pneumococcal conjugate vaccine (PCV15) demonstrates a favorable safety profile in healthy infants and other age groups.
• PCV15 was generally well-tolerated, with predominantly mild and transient adverse events.
• The findings support the continued investigation and potential use of PCV15 in infant immunization programs.